Kyverna Adds Legal Chief as It Preps for Commercial Launch
Event summary
- Kyverna Therapeutics appointed Ritesh Srivastava as Chief Legal and Compliance Officer on June 22, 2026.
- Srivastava received an option to purchase 260,000 shares of Kyverna’s common stock, vesting over four years.
- Kyverna is advancing miv-cel (KYV-101) towards a potential first approval in stiff person syndrome.
The big picture
Kyverna’s appointment of Srivastava underscores the strategic shift from clinical development to commercialization, a critical phase for biopharmaceutical companies transitioning to market-ready status. The move aligns with broader industry trends where legal and compliance leadership becomes pivotal in navigating regulatory approvals and scaling operations. Kyverna’s focus on miv-cel as a potential first-in-class therapy positions it at the forefront of autoimmune cell therapy innovation, though execution risks remain high.
What we're watching
- Regulatory Milestones
- The pace at which Kyverna advances its rolling BLA submission for miv-cel in stiff person syndrome.
- Commercialization Readiness
- How Srivastava’s experience will shape Kyverna’s transition to a commercial-stage organization.
- Pipeline Expansion
- Whether Kyverna can sustain momentum in its neuroimmunology franchise beyond stiff person syndrome.